|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 4 (February 15), 1999:
pp. 1271-1276
A Reduced Sensitivity for Activated Protein C in the Absence of
Factor V Leiden Increases the Risk of Venous Thrombosis
Marieke C.H. de Visser,
Frits R. Rosendaal, and
Rogier M. Bertina
From the Hemostasis and Thrombosis Research Center, Department of
Hematology, and the Department of Clinical Epidemiology, Leiden
University Medical Center, Leiden, The Netherlands.
Activated protein C (APC) resistance caused by the factor V Leiden
mutation is associated with an increased risk of venous thrombosis. We
investigated whether a reduced response to APC, not due to the factor V
point mutation, is also a risk factor for venous thrombosis. For this
analysis, we used the Leiden Thrombophilia Study (LETS), a case-control
study for venous thrombosis including 474 patients with a first
deep-vein thrombosis and 474 age- and sex-matched controls. All
carriers of the factor V Leiden mutation were excluded. A dose-response
relationship was observed between the sensitivity for APC and the risk
of thrombosis: the lower the normalized APC sensitivity ratio, the
higher the associated risk. The risk for the lowest quartile of
normalized APC-SR (<0.92), which included 16.5% of the healthy
controls, compared with the highest quartile (normalized APC-SR > 1.05) was greater than fourfold increased (OR = 4.4; 95%
confidence interval, 2.9 to 6.6). We adjusted for VIII:C levels, which
appeared to affect our APC resistance test. The adjusted (age, sex,
FVIII:C) odds ratio for the lowest quartile was 2.5 (95% confidence
interval, 1.5 to 4.2). So, after adjustment for factor VIII levels, a
reduced response to APC remained a risk factor. Our results show that a
reduced sensitivity for APC, not caused by the factor V Leiden
mutation, is a risk factor for venous thrombosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
J. Clin. Oncol.,
October 10, 2009;
27(29):
4865 - 4873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Majluf-Cruz, M. Moreno-Hernandez, A. Ruiz-de-Chavez-Ochoa, R. Monroy-Garcia, K. Majluf-Cruz, R. Guardado-Mendoza, I. Molina-Avila, I. Isordia-Salas, N. Corona-de la Pena, F. Vargas-Vorackova, et al.
Activated Protein C Resistance and Factor V Leiden in Mexico
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2008;
14(4):
428 - 437.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Minano, A. Ordonez, F. Espana, J. R. Gonzalez-Porras, R. Lecumberri, J. Fontcuberta, P. Llamas, F. Marin, A. Estelles, I. Alberca, et al.
AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms
Haematologica,
May 1, 2008;
93(5):
729 - 734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.S. Vieira, R.A. Ferriani, A.A. Garcia, M.C. Pintao, G.D. Azevedo, M.K.O. Gomes, and M.F. Silva-de-Sa
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade
Hum. Reprod.,
August 1, 2007;
22(8):
2196 - 2201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hemelaar, J. Rosing, P. Kenemans, M. C. L.G.D. Thomassen, D. D.M. Braat, and M. J. van der Mooren
Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women
Arterioscler Thromb Vasc Biol,
July 1, 2006;
26(7):
1660 - 1666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Glueck, P. Wang, H. Bell, V. Rangaraj, and N. Goldenberg
Associations of Thrombophilia, Hypofibrinolysis, and Retinal Vein Occlusion
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2005;
11(4):
375 - 389.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. J. Glueck, N. Goldenberg, H. Bell, K. Golnik, and P. Wang
Amaurosis Fugax: Associations with Heritable Thrombophilia
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2005;
11(3):
235 - 241.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Berger, M. Mattheisen, B. Kulle, H. Schmidt, J. Oldenburg, H. Bickeboller, U. Walter, T. H. Lindner, K. Strauch, and C. M. Schambeck
High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11
Blood,
January 15, 2005;
105(2):
638 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cushman
Inherited Risk Factors for Venous Thrombosis
Hematology,
January 1, 2005;
2005(1):
452 - 457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J.M. Doggen, N. L. Smith, R. N. Lemaitre, S. R. Heckbert, F. R. Rosendaal, and B. M. Psaty
Serum Lipid Levels and the Risk of Venous Thrombosis
Arterioscler Thromb Vasc Biol,
October 1, 2004;
24(10):
1970 - 1975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Castoldi, J. M. Brugge, G. A. F. Nicolaes, D. Girelli, G. Tans, and J. Rosing
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations
Blood,
June 1, 2004;
103(11):
4173 - 4179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ricci, F. Cerneca, R. Simeone, C. Pozzobon, S. Guarnieri, A. Sartore, R. Pregazzi, and S. Guaschino
Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial
Hum. Reprod.,
April 1, 2004;
19(4):
838 - 848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Esparza-Gordillo, J M Soria, A Buil, J C Souto, L Almasy, J Blangero, S R de Cordoba, and J Fontcuberta
Genetic correlation between plasma levels of C4BP isoforms containing {beta} chains and susceptibility to thrombosis
J. Med. Genet.,
January 1, 2004;
41(1):
e5 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. McBane II
Genetically Determined Procoagulant States and Heparin Use
Seminars in Cardiothoracic and Vascular Anesthesia,
December 1, 2003;
7(4):
427 - 442.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. W. F. T. Toorians, M. C. L. G. D. Thomassen, S. Zweegman, E. J. P. Magdeleyns, G. Tans, L. J. G. Gooren, and J. Rosing
Venous Thrombosis and Changes of Hemostatic Variables during Cross-Sex Hormone Treatment in Transsexual People
J. Clin. Endocrinol. Metab.,
December 1, 2003;
88(12):
5723 - 5729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Oger, M. Alhenc-Gelas, K. Lacut, M.-T. Blouch, N. Roudaut, V. Kerlan, M. Collet, J.-F. Abgrall, M. Aiach, P.-Y. Scarabin, et al.
Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial
Arterioscler Thromb Vasc Biol,
September 1, 2003;
23(9):
1671 - 1676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Post, M. Christella, L.G.D. Thomassen, M. J. van der Mooren, W. M. van Baal, J. Rosing, P. Kenemans, and C. D.A. Stehouwer
Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women
Arterioscler Thromb Vasc Biol,
June 1, 2003;
23(6):
1116 - 1121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Soria, L. Almasy, J. C. Souto, A. Buil, E. Martinez-Sanchez, J. Mateo, M. Borrell, W. H. Stone, M. Lathrop, J. Fontcuberta, et al.
A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility
Blood,
January 1, 2003;
101(1):
163 - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Folsom, M. Cushman, M. Y. Tsai, N. Aleksic, S. R. Heckbert, L. L. Boland, A. W. Tsai, N. D. Yanez, and W. D. Rosamond
A prospective study of venous thromboembolism in relation to factor V Leiden and related factors
Blood,
April 15, 2002;
99(8):
2720 - 2725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler Thromb Vasc Biol,
April 1, 2002;
22(4):
530 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Deguchi, J. A. Fernandez, and J. H. Griffin
Neutral Glycosphingolipid-dependent Inactivation of Coagulation Factor Va by Activated Protein C and Protein S
J. Biol. Chem.,
March 8, 2002;
277(11):
8861 - 8865.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Bauer
The Thrombophilias: Well-Defined Risk Factors with Uncertain Therapeutic Implications
Ann Intern Med,
September 4, 2001;
135(5):
367 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tripodi and P. M. Mannucci
Laboratory Investigation of Thrombophilia
Clin. Chem.,
September 1, 2001;
47(9):
1597 - 1606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Vandenbroucke, J. Rosing, K. W.M. Bloemenkamp, S. Middeldorp, F. M. Helmerhorst, B. N. Bouma, and F. R. Rosendaal
Oral Contraceptives and the Risk of Venous Thrombosis
N. Engl. J. Med.,
May 17, 2001;
344(20):
1527 - 1535.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rai, A. Shlebak, H. Cohen, M. Backos, Z. Holmes, K. Marriott, and L. Regan
Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage
Hum. Reprod.,
May 1, 2001;
16(5):
961 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Kamphuisen, J. C. J. Eikenboom, and R. M. Bertina
Elevated Factor VIII Levels and the Risk of Thrombosis
Arterioscler Thromb Vasc Biol,
May 1, 2001;
21(5):
731 - 738.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Seligsohn and A. Lubetsky
Genetic Susceptibility to Venous Thrombosis
N. Engl. J. Med.,
April 19, 2001;
344(16):
1222 - 1231.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Deguchi, J. A. Fernandez, I. Pabinger, J. A. Heit, and J. H. Griffin
Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway
Blood,
April 1, 2001;
97(7):
1907 - 1914.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Male, L. Mitchell, J. Julian, P. Vegh, P. Joshua, M. Adams, M. David, and M. E. Andrew
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus
Blood,
February 15, 2001;
97(4):
844 - 849.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-C. Gris, C. Jamin, J.-L. Benifla, I. Quere, P. Madelenat, and P. Mares
APC resistance and third-generation oral contraceptives: Acquired resistance to activated protein C, oral contraceptives and the risk of thromboembolic disease
Hum. Reprod.,
January 1, 2001;
16(1):
3 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tripodi, V. Chantarangkul, and P. Mannucci
Hyperprothrombinemia may result in acquired activated protein C resistance
Blood,
November 1, 2000;
96(9):
3295 - 3296.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kario, T. Sakata, T. Miyata, S. Kiechl, and J. Willeit
Is Acquired Activated Protein C Resistance a Cardiovascular Risk? • Response
Circulation,
March 28, 2000;
101
(12):
e120 - e120.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Lane and P. J. Grant
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
Blood,
March 1, 2000;
95(5):
1517 - 1532.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.M. Faioni, F. Franchi, P. Bucciarelli, M. Margaglione, V. De Stefano, G. Castaman, G. Finazzi, and P.M. Mannucci
Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden)
Blood,
November 1, 1999;
94(9):
3062 - 3066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Zivelin, S. Gitel, J. H. Griffin, X. Xu, J. A. Fernandez, U. Martinowitz, Y. Cohen, H. Halkin, U. Seligsohn, and A. Inbal
Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C
Blood,
August 1, 1999;
94(3):
895 - 901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Undas, E. B. Williams, S. Butenas, T. Orfeo, and K. G. Mann
Homocysteine Inhibits Inactivation of Factor Va by Activated Protein C
J. Biol. Chem.,
February 2, 2001;
276(6):
4389 - 4397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler Thromb Vasc Biol,
April 1, 2002;
22(4):
530 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
